{"id":945308,"date":"2026-03-18T08:05:23","date_gmt":"2026-03-18T12:05:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/"},"modified":"2026-03-18T08:05:23","modified_gmt":"2026-03-18T12:05:23","slug":"nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/","title":{"rendered":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2022 Baylor selects the Nautilus Voyager\u2122 Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit<\/em><br \/>\n        <br \/>\n        <em>\u2022 NIH-funded project leverages collaborators\u2019 expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis<\/em>\n      <\/p>\n<p>SEATTLE, March  18, 2026  (GLOBE NEWSWIRE) &#8212; Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus\u2019 Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus\u2019 novel single-molecule proteomics method to address a central challenge in cancer research \u2013 identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance \u2013 while Nautilus expands early commercial access to its validated tau proteoforms assay.<\/p>\n<p>The study, led by Baylor Professors Bing Zhang, Ph.D. and Yongchao Dou, Ph.D., aims to develop a broadly accessible computational toolkit with improved detection of protein isoforms in conventional shotgun proteomics datasets. By pairing these computational approaches with full-length, isoform-resolved proteomic measurements generated on the Nautilus Voyager\u2122 Platform, the project is intended to enable direct comparison of transcriptional and proteomic changes at unprecedented resolution.<\/p>\n<p>\u201cWe are excited to work with our first Iterative Mapping Early Access Program customer, Baylor College of Medicine, by providing Nautilus\u2019 single-molecule analysis platform as the ground truth for precise proteoform quantification,\u201d said Parag Mallick, Ph.D., Co-Founder and Chief Scientist of Nautilus Biotechnology. \u201cIn partnership with Drs. Bing Zhang and Yongchao Dou, and their distinguished teams, we aim to apply our Iterative Mapping approach towards formulating a deeper, more complete understanding of complex cancer biology.\u201d<\/p>\n<p>\u201cNautilus\u2019 protein analysis platform will complement our multi-omics expertise at Baylor by accurately identifying and quantifying the full diversity of protein isoforms across healthy and disease states,\u201d said Dr. Bing Zhang, Professor in the Lester and Sue Smith Breast Center and Department of Molecular and Human Genetics at Baylor. \u201cThe newfound ability to measure single-molecule proteins at high resolution through Iterative Mapping gives us an important reference that may illuminate connections between genomic and proteomic data in ways that haven\u2019t previously been possible.\u201d<\/p>\n<p>Researchers interested in the Early Access Program for Nautilus\u2019 platform can learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2QWrMbiDoyXyi9NktnVbOrkrExcGCkyZElgmO2wt09uBRuptvIClSGj7hjZzHUKIo0120hrVmQt1afUd4j2HM8yJcxCiArsFKg94z8JC0gFcZzvuPtmOrXWisQ33bx7c\" rel=\"nofollow\" target=\"_blank\">nautilus.bio\/nautilusEAP\/<\/a>.<\/p>\n<p>\n        <strong>About the Nautilus Voyager\u2122 Platform<\/strong><br \/>\n        <br \/>The Voyager Platform employs Nautilus\u2019 proprietary Iterative Mapping approach, which is designed to enable rapid measurement of intact single-molecule proteins and proteoforms. The platform&#8217;s flow cells are designed to accommodate up to 10 billion intact protein molecules, enabling measurement across an exceptionally wide dynamic range. Iterative Mapping independently probes single protein molecules across tens to hundreds of cycles, recording unique binding patterns for each individual molecule. Machine learning algorithms then convert the resulting probe-binding patterns into confident protein and proteoform identifications. Once analysis is complete, single-molecule counts are made available for download and further visualization. The Voyager instrument is designed for operational simplicity and standard lab benchtop placement, with a guided touchscreen user interface and minimal facility requirements, without need for bespoke gas or fluidic connections.<\/p>\n<p>\n        <strong>About Nautilus Biotechnology, Inc.<\/strong><br \/>\n        <br \/>With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create Voyager, a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus\u2019 mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eg6dsS_xNKXF6a5TpjfH4jf3y7VDUpZujZZYn-GSC36Un2NmVOydlSgWTV5SvxL0qQaLdx_joBeoe4XZOm7BIYZGhFif1i7NwFl3Zn9oitk=\" rel=\"nofollow\" target=\"_blank\"><u>www.nautilus.bio<\/u><\/a>.<\/p>\n<p>\n        <strong>Special Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus\u2019 expectations regarding the company\u2019s expectations with respect to the potential of its platform technology, its functionality and performance or its applicability in biological research and in potentially opening new avenues of research. These statements are based on numerous assumptions concerning the development of Nautilus\u2019 platform and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus\u2019 assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus\u2019 product platform is not yet commercially available and remains subject to scientific and technical development, which is inherently challenging and difficult to predict; we may experience material delays as a result of unanticipated events; we cannot provide any guarantee or assurance with respect to the outcome of our development. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-K filed for the year ended December 31, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.<\/p>\n<p>\n        <strong>Nautilus Media Contact<\/strong><br \/>\n        <br \/>press@nautilus.bio<\/p>\n<p>\n        <strong>Nautilus Investor Contact<\/strong><br \/>\n        <br \/>investorrelations@nautilus.bio<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWE3YTRkOGYtYTE4MS00Y2IwLTkyZjEtMTRkNTI3YTBhMThiLTEyMTk4NjUtMjAyNi0wMy0xOC1lbg==\/tiny\/Nautilus-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2022 Baylor selects the Nautilus Voyager\u2122 Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit \u2022 NIH-funded project leverages collaborators\u2019 expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus\u2019 Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus\u2019 novel single-molecule proteomics method to address a central challenge in cancer research \u2013 identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance \u2013 while Nautilus expands &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945308","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2022 Baylor selects the Nautilus Voyager\u2122 Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit \u2022 NIH-funded project leverages collaborators\u2019 expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus\u2019 Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus\u2019 novel single-molecule proteomics method to address a central challenge in cancer research \u2013 identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance \u2013 while Nautilus expands &hellip; Continue reading &quot;Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:05:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform\",\"datePublished\":\"2026-03-18T12:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/\"},\"wordCount\":905,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/\",\"name\":\"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\",\"datePublished\":\"2026-03-18T12:05:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/","og_locale":"en_US","og_type":"article","og_title":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk","og_description":"\u2022 Baylor selects the Nautilus Voyager\u2122 Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit \u2022 NIH-funded project leverages collaborators\u2019 expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) &#8212; Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus\u2019 Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus\u2019 novel single-molecule proteomics method to address a central challenge in cancer research \u2013 identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance \u2013 while Nautilus expands &hellip; Continue reading \"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T12:05:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform","datePublished":"2026-03-18T12:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/"},"wordCount":905,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/","name":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=","datePublished":"2026-03-18T12:05:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3MzkxNCM3NDkwNDM0IzIyMDgzMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945308"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945308\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}